title: [Proton pump inhibitors in developmental period medicine].
abstract: Proton pump inhibitors (PPI) are characterized by high effectiveness, selectivity and few adverse events. Development of PPI was an important issue in aspect of acid-related diseases treatment. Nowadays following PPI are available on the market: omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole. In children these drugs are the most frequently use in gastritis and duodenitis, ulcer disease with coexistence of Helicobacter pylori infection and gastroesophageal reflux disease. Pharmacokinetics of PPI is slightly different in children than in adults and so far there is a lack of randomised studies assessing the efficacy of PPI i developmental period medicine on numerous groups of patients. In our study literature review of PPI use in children and youth was presented.
authors.affiliation: Uniwersytet Mikołaja Kopernika w Toruniu, Collegium Medicum w Bydgoszczy, Katedra i Klinika Pediatrii, Alergologii i Gastroenterologii. klped@cm.umk.pl
authors.forename: Mieczysława
authors.initials: M
authors.lastname: Czerwionka-Szaflarska
authors.forename: Jerzy
authors.initials: J
authors.lastname: Brazowski
mesh_terms: D000328:Adult; D000367:Age Factors; D000897:Anti-Ulcer Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D004347:Drug Interactions; D004382:Duodenitis / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D064098:Esomeprazole; D005756:Gastritis / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D016481:Helicobacter Infections / Q000188:drug therapy; D006801:Humans; D009853:Omeprazole / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy; D054328:Proton Pump Inhibitors
chemical_list: D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D009853:Omeprazole; D064098:Esomeprazole